Lead Product(s) : Cymerus Mesenchymal Stem Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
Details : Treatment with Cynata’s Cymerus MSCs led to statistically significant improvements in multiple harmful effects of IPF, including interstitial fibrosis, dynamic lung compliance and airway resistance.
Product Name : CYP-006TK
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 09, 2020
Lead Product(s) : Cymerus Mesenchymal Stem Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable